Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

TScan Therapeutics, Inc. - Common Stock (NQ:TCRX)

1.780 +0.010 (+0.56%)
Streaming Delayed Price Updated: 11:44 AM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about TScan Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer
Dr. Louis brings to TScan extensive experience in cell therapy, medical affairs, and clinical and commercial development 
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition
Company to host virtual KOL event featuring Monzr M. Al Malki, M.D., on Monday, December 11, at 8:00 a.m. ET to discuss the data presented at the ASH Annual Meeting 
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in Upcoming Investor Conferences
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME
TSC-203-A0201 is TScan’s fourth TCR-T cell product cleared for use in its solid tumor program, designed to enable customized, multiplexed TCR-T cell therapy 
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Transition of Chief Financial Officer
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors
TSC-200-A0201 is TScan’s third cleared IND for the T-Plex solid tumor program supporting the use of multiple TCRs in combination to deliver customized, multiplexed TCR-T cell therapies based on target... 
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Closing of Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics to Participate in the Jefferies Healthcare Conference
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Pricing of $140 Million Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Announces Launch of Proposed Public Offering
From TScan Therapeutics, Inc.
Via GlobeNewswire
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
From TScan Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.